Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H21N |
Molecular Weight | 263.3767 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13
InChI
InChIKey=BWPIARFWQZKAIA-UHFFFAOYSA-N
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00344 | https://www.drugs.com/pro/protriptyline.html | http://reference.medscape.com/drug/vivactil-protriptyline-342945 | https://www.ncbi.nlm.nih.gov/pubmed/26988801 | https://www.ncbi.nlm.nih.gov/pubmed/20804147
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00344 | https://www.drugs.com/pro/protriptyline.html | http://reference.medscape.com/drug/vivactil-protriptyline-342945 | https://www.ncbi.nlm.nih.gov/pubmed/26988801 | https://www.ncbi.nlm.nih.gov/pubmed/20804147
Protriptyline (trade name Vivactil) is a tricyclic antidepressant, indicated for the treatment of depression. Protriptyline acts by decreasing the reuptake of norepinephrine and to a lesser extent serotonin (5-HT) in the brain. Tricyclic antidepressants act to change the balance of naturally occurring chemicals in the brain that regulate the transmission of nerve impulses between cells. Protriptyline increases the concentration of norepinephrine and serotonin (both chemicals that stimulate nerve cells) and, to a lesser extent, blocks the action of another brain chemical, acetylcholine. The therapeutic effects of protriptyline, like other antidepressants, appear slowly. Maximum benefit is often not evident for at least two weeks after starting the drug. Protriptyline is used primarily to treat depression and to treat the combination of symptoms of anxiety and depression. Like most antidepressants of this chemical and pharmacological class, protriptyline has also been used in limited numbers of patients to treat panic disorder, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, enuresis, eating disorders such as bulimia nervosa, cocaine dependency, and the depressive phase of bipolar disorder (manic-depressive) disorder. It has also been used to support smoking cessation programs. Like all tricyclic antidepressants, protriptyline should be used cautiously and with close physician supervision. This is especially so in the elderly, or people who have benign prostatic hypertrophy (enlarged prostate gland), or urinary retention, or glaucoma, especially angle-closure glaucoma (the most severe form). Before starting treatment, people should discuss the relative risks and benefits of treatment with their doctors to help determine if protriptyline is the right antidepressant for them. A common problem with tricyclic antidepressants is sedation (drowsiness, lack of physical and mental alertness), but protriptyline is considered the least sedating agent among this class of agents. Its side effects are especially noticeable early in therapy. In most people, early tricyclic side-effects decrease or disappear entirely with time, but, until then, patients taking protriptyline should take care to assess which side-effects occur in them and should not perform hazardous activities requiring mental acuity or coordination. The side-effects are increased when protriptyline is taken with central nervous system depressants, such as alcoholic beverages, sleeping medications, other sedatives, or antihistamines, as well as with other antidepressants including SSRIs, SNRIs or monoamine oxidase Inhibitors.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26988801 |
2.8 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VIVACTIL Approved UseProtriptyline Hydrochloride Tablets, USP are indicated for the treatment of symptoms of mental depression in patients who are under close medical supervision. Its activating properties make it particularly suitable for withdrawn and anergic patients. Launch Date1967 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/639433/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROTRIPTYLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1448 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/639433/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROTRIPTYLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
74.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/639433/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROTRIPTYLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
High-performance liquid chromatographic analysis for a non-chromophore-containing phosphatidyl inositol analog, 1-((1-O-octadecyl-2-O-methyl-sn-glycero)phospho)-1D-3-deoxy-myo-inositol, using indirect UV detection. | 2001 Apr 13 |
|
Painful ejaculation and urinary hesitancy in association with antidepressant therapy: relief with tamsulosin. | 2002 Aug |
|
The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. | 2002 Oct |
|
Tricyclic antidepressants as long-acting local anesthetics. | 2003 May |
|
Pharmacotherapies for obstructive sleep apnoea: where are we now? | 2004 |
|
Hypersomnia. | 2005 |
|
Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant? | 2005 Mar |
|
Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial. | 2005 Sep |
|
Narcolepsy: treatment issues. | 2007 |
|
Protriptyline block of the human ether-à-go-go-related gene (HERG) K+ channel. | 2008 Jan 30 |
|
Determination of tricyclic antidepressants in human plasma using pipette tip solid-phase extraction and gas chromatography-mass spectrometry. | 2008 Jul |
|
Narcolepsy: current treatment options and future approaches. | 2008 Jun |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Tricyclic antidepressants and headaches: systematic review and meta-analysis. | 2010 Oct 20 |
|
In vitro studies of DNA damage caused by tricyclic antidepressants: a role of peroxidase in the side effects of the drugs. | 2010 Sep 20 |
Sample Use Guides
Usual Adult Dosage
Fifteen to 40 mg a day divided into 3 or 4 doses. If necessary, dosage may be increased to 60 mg a day. Dosages
above this amount are not recommended. Increases should be made in the morning dose.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20804147
The standard reaction mixture with calf thymus DNA contained (unless otherwise specified) 0.2 μM HRP, 13 μM per bp calf thymus DNA (∼10 ng/μL), 500 μM Protriptyline, and 500 μM H2O2 in Sorenson buffer (pH 7.0) containing 67 mM dibasic sodium phosphate and 67 mM monobasic potassium phosphate.
The standard reaction mixture with pBR322 plasmid contained 0.2 μM HRP, 3 ng/μL (∼5 μM per bp) plasmid, 500 μM Protriptyline, and 500 μMH2O2 in 67 mM Sorenson buffer (pH 7.0). The volume of the reaction mixtures prepared for the 15-well gels was 10 μL; the volume of the reactions prepared for 8-well gels was 20 μL. The components were added in the order listed. All reaction mixtures were incubated at 37 C for 1 h in a water bath.
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N06AA11
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
NDF-RT |
N0000175752
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
LIVERTOX |
NBK548310
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
WHO-VATC |
QN06AA11
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
NCI_THESAURUS |
C94727
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D011530
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
1663
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
PROTRIPTYLINE
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
7285
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
4NDU154T12
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
Protriptyline
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
CHEMBL668
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
m9280
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | Merck Index | ||
|
3391
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
8886
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | RxNorm | ||
|
4976
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
SUB10145MIG
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
438-60-8
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
2320
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
8598
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
DTXSID0023535
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
DB00344
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
8597
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
4NDU154T12
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
C61913
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
207-119-9
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
100000080857
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)